A targeted approach to infectious diseases and microbiology

Transcription

1

2 What is a Technological Research Institute? A Technological Research Institute is an interdisciplinary institute bringing together industry and public research skills through medium-to long-term strategic public/private cooperation. A targeted approach to infectious diseases and microbiology Organized by its founders with its own legal statutes as a Foundation for Scientific Cooperation, BIOASTER possesses infrastructures and skills dedicated to: Pilot research programs focused on technology and products Carry out experimental and technological research and development activities Contribute to the development of pre- and post-graduate training programs Conduct socio-economic evaluations of research results. Co-funded by the French State and private partners, it has an independent management team dedicated to: Select, support and manage a portfolio of internal and cooperative R&D projects Develop and manage technical platforms to support projects Create added value from the Industrial Property generated through funded or co-funded projects, in order to become sustainable in the medium to long term. A Technological Research Institute is expected to foster ecosystems composed of competitiveness clusters whose goals are to achieve excellence and contribute to strengthening the competitiveness of the economic sector as a whole, in order to create value and employment. Based in France, BIOASTER s assets include its two major biotech ecosystems located in Lyon (Rhône-Alpes) and Paris (Île-de-France). BIOASTER intends to meet the major public health challenges related to infectious diseases which are responsible for over 17 million deaths worldwide each year: respiratory diseases, diarrheal diseases, AIDS, tuberculosis, malaria, sepsis, etc. Its application fields are anti-infectious drugs, human and animal vaccines, diagnostics and probiotics. BIOASTER is the only health-related Technological Research Institute in France, selected by the General Commission for Investments within the framework of a call for proposals of the Investments for the Future Program. It is dedicated to infectious diseases and microbiology, and tasked with enhancing scientific knowledge, technological know-how and innovation to foster economic development.

3 A NEW KEY PLAYER DRIVEN BY A STRONG ENTREPRENEURIAL DYNAMIC Toward better management of infectious diseases and advances in microbiology One vision Provide a comprehensive and personalized approach to infectious diseases and microbiology. One ambition Establish health firms in the region and foster the emergence of intermediate companies and the growth of small- and mediumsized businesses (SMBs) through a project focused on economic and industrial development. One aim Become a leader in infectious diseases and microbiology research and development. Raising substantial resources Support from the French state within the framework of the Investments for the Future Program Involvement of academic research Commitment of major industrial players A dynamic entrepreneurial network An international Scientific Advisory Board to address scientific issues of the Institute. With all of its partners, BIOASTER will strengthen the role and the international prestige of our country the in field of biology and life sciences. Alain Mérieux - BIOASTER President the fie Bringing together major innovation partners BIOASTER is at a cross-road of know-how and innovation through the meeting of talents. BIOASTER falls today within the scope of a Foundation for Scientific Cooperation and Research, created with public and private funds. BIOASTER gathers 8 founding members: Lyonbiopole and the Institut Pasteur, three major industrial companies - Sanofi, Institut Mérieux, Danone Research - and three academic research centers - INSERM, CNRS, and CEA - as well as a group comprising 40 SMBs (small- and medium-sized businesses) from the Rhône-Alpes and Paris areas. Within the Board of Directors of the Foundation, its founding members sit alongside two representatives from the economic field (including one SMB) and one representative of teachers, researchers and lecturers.

4 2012: BIOASTER set in motion APRIL 19 TH, 2012 Publication of BIOASTER s Foundation for Scientific Cooperation statutes in the Journal officiel de la République française MAY 2 ND, 2012 First BIOASTER s Board of Directors and election of its President, Alain Mérieux FALL 2012 Launch of the first projects and technical platforms Working toward a campus recognized worldwide An ambitious, long-term real estate plan to acquire up to 400,000 sq.ft./35,000 sq.m. New facilities will be built in Lyon-Gerland (France), a main site which will be associated with a second site within the Institut Pasteur in Paris. Two centers of excellence in France will host BIOASTER s technological platforms and research teams Key figures In the first 3 years up to 40 R&D projects to be started with 90 M to be invested by private stakeholders and local authorities Within 9 years, an ambitious prospect More than 700 researchers Up to 400,000 sq.ft./ 35,000 sq.m. of new facilities A cumulative budget of 585 M 180 M in public grants Charles Mérieux Campus in Lyon-Gerland More than 3,000 researchers and skilled scientists in the biotechnology and healthcare sectors 750 researchers and technicians in life sciences International R&D infrastructures such as the Jean Mérieux BSL4 laboratory Global industrial players: Sanofi, Sanofi Pasteur, Merial, Genzyme, Institut Mérieux The Institut Pasteur in Paris 2,600 people 130 research entities organized in 10 thematic departments 14 technological platforms 10 Nobel Prize laureates.

5 A UNIQUE MODEL FOR INNOVATION IN INFECTIOLOGY & MICROBIOLOGY 3 R&D STRUCTURING PROGRAMS 5 TECHNOLOGICAL PLATFORMS Collection and characterization of pathogens New therapies and vaccines Toward real time diagnosis Microbiota: an indicator and a healthcare product Host and host response Biomanufacturing by design Drug and vaccine prototyping technologies New therapeutic, prophylactic and diagnostic products New technologies and high added-value core departments ICT * AND DATA MANAGEMENT A multidisciplinary and innovative approach BIOASTER will conduct its in-house R&D cross-disciplinary activities at the interface of upstream research and industrialization, bridging a missing link to ensure an optimal chain of R&D in infectious diseases and microbiology. BIOASTER brings together complementary industrial and academic players (life sciences, physical, mechanical, chemical, and bioinformatics). Synergies between these players will allow innovative products and new services to enter the market quickly. 3 R&D STUCTURING PROGRAMS 1. New therapies and vaccines The program will focus on developing the following: Antibacterials, antifungals, antiparatics and antivirals, designed around methods that are closer to natural mechanisms, and drawing on the knowledge of interactions between infectious pathogens, cells and hosts New immuno-modulatory treatments made possible by a comprehensive understanding of the host response to infection New vaccines that enable preventive or curative treatment of microorganisminduced illnesses, with lower resistance levels due to the combination of complementary methods New original innovative products can be created by integrating the metabolic approach into the proposed therapeutic strategies Personalized methodology for the treatment and prevention of infectious diseases. 2. Toward real time diagnosis The aim of this program is to develop new diagnostics making it possible to predict infections and identify pathogen(s) rapidly. This enables personalized management against infections and immediate prescription of the adapted treatments. 3. Microbiota: an indicator and a healthcare product The aim of this program is to advance the scientific concepts of predictive microbiota (indicator of health, homeostasis) and therapeutic microbiota (probiotics) in order to develop new varieties of diagnostic, therapeutic, and preventive products. It fully integrates into an approach toward preventive medicine and nutrition. 5 TECHNOLOGICAL PLATFORMS The implementation of R&D programs will rely on five high-level platforms offering: Competencies and infrastructural equipment to help develop state-ofthe-art technologies Services provided with SMBs Development of R&D projects with an emphasis on technology. BIOASTER will set up a structure dedicated to deriving the maximum benefit from research results, patents and products developed within the Institute. * Information and Communication Technologies

6 JOIN BIOASTER: A WINNING FORMULA TO STRENGTHEN YOUR COMPETITIVENESS BIOASTER represents a strong link in the chain of innovation in infectious diseases and microbiology: an exclusive opportunity to co-invest in completely new approaches, to share risk among industrials, SMBs, and academic organizations, and to utilize technical resources and complementary skills that support your activities. Becoming part of a dynamic network of SMBs What sets BIOASTER apart and makes it particularly promising is the fact that it involves some forty SMBs from the Rhône-Alpes and Paris regions. BIOASTER can offer SMBs: High-level technical facilities Enhanced expertise by sharing with all partners Assistance in developing new services Access to a larger portfolio of collaborative ventures Growth opportunities to become a medium-sized company Further promotion and greater international recognition Greater research volumes and services Privileged access to innovation and breakthrough technologies Over time, stronger economic growth. Anchoring major industrial companies in the area The strong involvement of major French companies engaged in infectious diseases and microbiology research (Sanofi, Sanofi Pasteur, biomérieux, Merial, Danone Research ) demonstrates the value of BIOASTER s project, which will provide: A single source of skills, expertise and resources Techniques in their field of activity to accelerate the development of innovative products and strengthen their industrial sectors Large engineering and international facilities Access to top-level academic resources Strong incentives to attract international companies seeking to further their economic and industrial significance in the area Leading-edge technical services. Creating value together BIOASTER has a positive knock-on effect on the level of resources and knowledge from the early research stage through product development, due to: Multidisciplinary skills and state-of-the-art facilities Risk sharing and expansion of scientific approaches related to projects New technological and industrial opportunities Advancement for economic growth and jobs creation Cross-sector and interdisciplinary research approaches.

7 TECHNOLOGICAL RESEARCH INSTITUTE CONTACT BIOASTER - Bâtiment Domilyon 321, avenue Jean-Jaurès Lyon FRANCE Tel: +33 (0) FOUNDERS SUPPORTED BY LOCAL AUTHORITIES / THERA Conseil / RCS Lyon B / Photos: Sanofi Institut Mérieux: C. Ganet, L. Bouchut, S. Audras GraphicObsession Getty Images Fotolia IRT BIOASTER aerial view Asylum for Grand Lyon.